X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mianserin - analogs & derivatives (1249) 1249
humans (1109) 1109
male (819) 819
mianserin - therapeutic use (741) 741
female (676) 676
mirtazapine (611) 611
psychiatry (557) 557
adult (546) 546
middle aged (464) 464
index medicus (430) 430
mianserin - adverse effects (423) 423
pharmacology & pharmacy (421) 421
antidepressive agents, tricyclic - therapeutic use (406) 406
mianserin - pharmacology (356) 356
aged (290) 290
animals (282) 282
treatment outcome (279) 279
antidepressive agents, tricyclic - adverse effects (264) 264
depressive disorder - drug therapy (257) 257
antidepressants (256) 256
mianserin - administration & dosage (237) 237
neurosciences (237) 237
clinical neurology (204) 204
depressive disorder, major - drug therapy (198) 198
rats (185) 185
depression (184) 184
major depression (184) 184
antidepressive agents - therapeutic use (172) 172
dose-response relationship, drug (150) 150
drug therapy, combination (147) 147
double-blind method (146) 146
depression - drug therapy (145) 145
double-blind (137) 137
antidepressive agents, tricyclic - pharmacology (136) 136
psychiatric status rating scales (133) 133
antidepressive agents, tricyclic - administration & dosage (120) 120
serotonin uptake inhibitors - therapeutic use (120) 120
venlafaxine hydrochloride (118) 118
adolescent (107) 107
antidepressant (106) 106
time factors (104) 104
efficacy (103) 103
fluoxetine (99) 99
mianserin (99) 99
serotonin (97) 97
antidepressive agents - pharmacology (94) 94
psychology, clinical (94) 94
antidepressive agents - adverse effects (89) 89
antidepressive agents, second-generation - therapeutic use (85) 85
aged, 80 and over (84) 84
cyclohexanols - therapeutic use (82) 82
depressive disorder - psychology (82) 82
mianserin - pharmacokinetics (78) 78
young adult (77) 77
drug interactions (74) 74
major depressive disorder (73) 73
mianserin - blood (73) 73
depression, mental (68) 68
drug administration schedule (68) 68
adrenergic alpha-antagonists - therapeutic use (67) 67
amitriptyline (66) 66
serotonin uptake inhibitors - adverse effects (66) 66
venlafaxine (66) 66
paroxetine (64) 64
drugs (63) 63
analysis (62) 62
psychology (62) 62
adrenergic alpha-antagonists - pharmacology (61) 61
rats, wistar (61) 61
depressive disorder, major - psychology (60) 60
drug therapy (60) 60
placebo (60) 60
rats, sprague-dawley (59) 59
serotonin reuptake inhibitors (57) 57
severity of illness index (57) 57
serotonin antagonists - pharmacology (54) 54
antipsychotic agents - therapeutic use (53) 53
analysis of variance (52) 52
antidepressive agents - administration & dosage (52) 52
receptors (52) 52
antidepressive agents, second-generation - adverse effects (51) 51
citalopram - therapeutic use (50) 50
pharmacokinetics (50) 50
care and treatment (49) 49
comorbidity (49) 49
receptors, serotonin - drug effects (48) 48
mice (47) 47
medicine, general & internal (46) 46
tolerability (46) 46
antidepressive agents, tricyclic - pharmacokinetics (45) 45
schizophrenia (45) 45
prospective studies (44) 44
risk factors (44) 44
sleep (43) 43
depressive disorder, major - diagnosis (42) 42
fluoxetine - therapeutic use (42) 42
serotonin uptake inhibitors - pharmacology (42) 42
anxiety (41) 41
cyclohexanols - adverse effects (41) 41
antipsychotic agents - adverse effects (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1299) 1299
German (23) 23
Japanese (14) 14
Spanish (10) 10
Hungarian (8) 8
Polish (7) 7
French (6) 6
Russian (5) 5
Dutch (4) 4
Danish (3) 3
Chinese (2) 2
Lithuanian (2) 2
Portuguese (2) 2
Swedish (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2018, Volume 2018, Issue 8, p. CD012708
Journal Article
Psychopharmacology, ISSN 0033-3158, 8/2016, Volume 233, Issue 15, pp. 2955 - 2971
Fas-associated death domain (FADD) is an adaptor of death receptors that can also induce anti-apoptotic actions through its phosphorylated form (p-FADD).... 
Neuroplasticity | Neuroprotection | Neurosciences | Biomedicine | FADD and p-FADD | Forced swim test | Anti-depressant drugs | Pharmacology/Toxicology | Psychiatry | Electroconvulsive shock | PRESYNAPTIC AUTORECEPTORS | NEUROTRANSMITTER RELEASE | PSYCHIATRY | ANTIDEPRESSANT TREATMENT | ADRENERGIC-RECEPTOR | MAJOR DEPRESSION | SUICIDE VICTIMS | NEUROSCIENCES | PREFRONTAL CORTEX | MONOAMINE-OXIDASE INHIBITORS | PHARMACOLOGY & PHARMACY | GAMMA-AMINOBUTYRIC-ACID | DEATH DOMAIN PROTEIN | Phosphoproteins - drug effects | Phenelzine - pharmacology | Autoreceptors - metabolism | Clorgyline - pharmacology | Male | Adrenergic alpha-Antagonists - pharmacology | Phosphoproteins - metabolism | Cerebral Cortex - metabolism | Idazoxan - pharmacology | Mianserin - analogs & derivatives | Mianserin - pharmacology | Desipramine - pharmacology | Fluoxetine - analogs & derivatives | Mirtazapine | Antidepressive Agents - pharmacology | Cerebral Cortex - drug effects | Phosphorylation - drug effects | RNA-Binding Proteins - antagonists & inhibitors | Fluoxetine - pharmacology | Idazoxan - analogs & derivatives | Monoamine Oxidase Inhibitors - pharmacology | Fas-Associated Death Domain Protein - drug effects | Norepinephrine Plasma Membrane Transport Proteins - antagonists & inhibitors | Fas-Associated Death Domain Protein - metabolism | Rats | Excitatory Amino Acid Antagonists - pharmacology | Blotting, Western | Brain - drug effects | Animals | CASP8 and FADD-Like Apoptosis Regulating Protein | Thiazoles - pharmacology | Ketamine - pharmacology | Electroshock | Apoptosis | Indans - pharmacology | Pharmacology, Experimental | Antidepressants | Desipramine | Fluoxetine | Psychopharmacology | Dosage and administration | Research | Proteins | Brain | Rodents
Journal Article
American Journal of Psychiatry, ISSN 0002-953X, 06/2015, Volume 172, Issue 6, pp. 512 - 516
CONTROLLED-TRIAL | INJECTION-DRUG USERS | SELF-ADMINISTERED THERAPY | VIRUS-INFECTION | PSYCHIATRY | DIRECTLY OBSERVED THERAPY | GENOTYPE 1 INFECTION | ANTIRETROVIRAL THERAPY | MENTAL-ILLNESS | PEGYLATED INTERFERON-ALPHA | TREATMENT-NAIVE PATIENTS | Mianserin - adverse effects | Recombinant Proteins - therapeutic use | Simeprevir | Humans | Middle Aged | Citalopram - adverse effects | Mianserin - therapeutic use | Polyethylene Glycols - adverse effects | Depressive Disorder - drug therapy | Male | Recombinant Proteins - adverse effects | Physician's Role - psychology | Polyethylene Glycols - therapeutic use | Dose-Response Relationship, Drug | Mianserin - analogs & derivatives | Depressive Disorder - chemically induced | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Cooperative Behavior | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Forecasting | Antidepressive Agents - therapeutic use | Interdisciplinary Communication | Proline - therapeutic use | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Uridine Monophosphate - analogs & derivatives | Proline - adverse effects | Sulfonamides - adverse effects | Citalopram - therapeutic use | Interferon-alpha - adverse effects | Antidepressive Agents - adverse effects | Depressive Disorder - psychology | Hepatitis C, Chronic - psychology | Drug Substitution | Sofosbuvir | Delirium - chemically induced
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10047, pp. 881 - 890
Summary Background Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological... 
Internal Medicine | TRIALS | MEDICINE, GENERAL & INTERNAL | ACCEPTABILITY | MENTAL-HEALTH-CARE | TRENDS | GUIDELINES | Mianserin - adverse effects | Triazoles - administration & dosage | Triazoles - adverse effects | Humans | Citalopram - adverse effects | Sertraline - adverse effects | Venlafaxine Hydrochloride - adverse effects | Imipramine - administration & dosage | Paroxetine - adverse effects | Mianserin - analogs & derivatives | Paroxetine - administration & dosage | Desipramine - adverse effects | Nortriptyline - administration & dosage | Nortriptyline - adverse effects | Mianserin - administration & dosage | Child | Fluoxetine - adverse effects | Depressive Disorder, Major - drug therapy | Clomipramine - administration & dosage | Duloxetine Hydrochloride - adverse effects | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Clomipramine - adverse effects | Evidence-Based Medicine | Desipramine - administration & dosage | Randomized Controlled Trials as Topic | Venlafaxine Hydrochloride - administration & dosage | Citalopram - administration & dosage | Confounding Factors (Epidemiology) | Sertraline - administration & dosage | Adolescent | Amitriptyline - adverse effects | Bayes Theorem | Fluoxetine - administration & dosage | Duloxetine Hydrochloride - administration & dosage | Antidepressive Agents - administration & dosage | Antidepressive Agents - adverse effects | Research Design | Amitriptyline - administration & dosage | Imipramine - adverse effects | Psychological aspects | Medical colleges | Neurosciences | Drugs and youth | Rankings | Comparative analysis | Child psychopathology | Major depressive disorder | Antidepressants, Tricyclic | Pediatric pharmacology | Mental illness | Studies | Teenagers | Mental depression | Antidepressants | Meta-analysis | Children & youth
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9789, pp. 403 - 411
Journal Article